Acromegaly is characterized by increased release of growth hormone and, consequently, insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to excess hormone leads to progressive somatic disfigurement and a wide range of systemic manifestations that are associated with increased mortality. Although considered a rare disease, recent studies have reported an increased incidence of acromegaly owing to better disease awareness, improved diagnostic tools and perhaps a real increase in prevalence. Acromegaly treatment approaches, which include surgery, radiotherapy and medical therapy, have changed considerably over time owing to improved surgical procedures, development of new radiotherapy techniques and availability of new medical therapies. The optimal use of these treatments will reduce mortality in patients with acromegaly to levels in the general population. Medical therapy is currently an important treatment option and can even be the first-line treatment in patients with acromegaly who will not benefit from or are not suitable for first-line neurosurgical treatment. Pharmacological treatments include somatostatin receptor ligands (such as octreotide, lanreotide and pasireotide), dopamine agonists and the growth hormone receptor antagonist pegvisomant. In this Primer, we review the main aspects of acromegaly, including scientific advances that underlie expanding knowledge of disease pathogenesis, improvements in disease management and new medical therapies that are available and in development to improve disease control.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases
Scientific Reports Open Access 23 September 2022
Journal of Endocrinological Investigation Open Access 14 June 2021
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $79.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Marie, P. Sur Deux Cas D’acromégalie; Hypertrophie Singulière non Congénitale des Extrémités Supérieures, Inférieures et Céphalique [French] (F. Alcan, 1886).
de Herder, W. W. The history of acromegaly. Neuroendocrinology 103, 7–17 (2016).
Verga, A. Caso singolare de prosopectasia [Italian]. Reale Istituto Lombardo Scienze Lett. Rendiconti Classe Scienze Matematiche Naturali 1, 111–117 (1864).
Lombroso, C. Caso singolare di macrosomia simulante [Italian]. Giornale Ital. Malattie Veneree Malattie Pelle 2, 129–135 (1868).
Wier, J. in Virgo Gygantea ex Quartana Reddita [Latin] 7–10 (Oporinus, Basel, Switzerland, 1567).
Brigidi, V. Studii anatomopatologica sopra un uomo divenuto stranamente deforme per chronica infirmita [Italian]. Soc. Med. Fis. Fiorentina (1877).
Petrossians, P. et al. Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr. Relat. Cancer 24, 505–518 (2017). This paper describes trends in acromegaly characteristics over time, using data from the Liège Acromegaly Survey (LAS) database.
Hannah-Shmouni, F., Trivellin, G. & Stratakis, C. A. Genetics of gigantism and acromegaly. Growth Horm. IGF Res. 30–31, 37–41 (2016).
Katznelson, L. et al. Acromegaly: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014). This article presents the most recent acromegaly guidelines from the Endocrine Society to address important clinical issues regarding the evaluation and management of acromegaly.
Colao, A., Ferone, D., Marzullo, P. & Lombardi, G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25, 102–152 (2004).
Pivonello, R. et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20, 46–62 (2017).
Lombardi, G. et al. The cardiovascular system in growth hormone excess and growth hormone deficiency. J. Endocrinol. Invest. 35, 1021–1029 (2012).
Ribeiro-Oliveira, A. Jr & Barkan, A. The changing face of acromegaly—advances in diagnosis and treatment. Nat. Rev. Endocrinol. 8, 605–611 (2012).
Langlois, F., McCartney, S. & Fleseriu, M. Recent progress in the medical therapy of pituitary tumors. Endocrinol. Metab. (Seoul) 32, 162–170 (2017).
Melmed, S. New therapeutic agents for acromegaly. Nat. Rev. Endocrinol. 12, 90–98 (2016). This Review outlines the need for new therapeutic agents for patients with acromegaly to improve disease control and patient compliance.
Colao, A., Auriemma, R. S., Pivonello, R., Galdiero, M. & Lombardi, G. Medical consequences of acromegaly: what are the effects of biochemical control? Rev. Endocr. Metab. Disord. 9, 21–31 (2008).
Vierimaa, O. et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312, 1228–1230 (2006).
Daly, A. F. et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab. 95, E373–E383 (2010).
Trivellin, G. et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N. Engl. J. Med. 371, 2363–2374 (2014).
Colao, A., Auriemma, R. S., Pivonello, R., Kasuki, L. & Gadelha, M. R. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19, 235–247 (2016).
Ben-Shlomo, A., Sheppard, M. C., Stephens, J. M., Pulgar, S. & Melmed, S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14, 284–294 (2011).
Colao, A., Auriemma, R. S., Lombardi, G. & Pivonello, R. Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32, 247–271 (2011). This critical analysis of the literature on the efficacy of SRLs in the treatment of acromegaly is an effort to offer a potential definition of SRL resistance.
Alexander, L., Appleton, D., Hall, R., Ross, W. M. & Wilkinson, R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. 12, 71–79 (1980).
Bengtsson, B. A., Eden, S., Ernest, I., Oden, A. & Sjogren, B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med. Scand. 223, 327–335 (1988).
Hoskuldsdottir, G. T., Fjalldal, S. B. & Sigurjonsdottir, H. A. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary 18, 803–807 (2015).
Agustsson, T. T. et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur. J. Endocrinol. 173, 655–664 (2015).
Gruppetta, M., Mercieca, C. & Vassallo, J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16, 545–553 (2013).
Tjornstrand, A. et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur. J. Endocrinol. 171, 519–526 (2014).
Mestron, A. et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia. REA). Eur. J. Endocrinol. 151, 439–446 (2004).
Dal, J. et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175, 181–190 (2016).
Daly, A. F. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769–4775 (2006).
Lavrentaki, A., Paluzzi, A., Wass, J. A. & Karavitaki, N. Epidemiology of acromegaly: review of population studies. Pituitary 20, 4–9 (2017).
Esposito, D. et al. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur. J. Endocrinol. 178, 459–469 (2018).
Chen, C. J. et al. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir. (Wien) 159, 2193–2207 (2017).
Antunes, X. et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 60, 415–422 (2018).
Frara, S., Maffezzoni, F., Mazziotti, G. & Giustina, A. The modern criteria for medical management of acromegaly. Prog. Mol. Biol. Transl Sci. 138, 63–83 (2016).
Fernandez, A., Karavitaki, N. & Wass, J. A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72, 377–382 (2010).
Giustina, A. et al. Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. J. Endocrinol. Invest. 31, 731–738 (2008).
De Menis, E. et al. Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. J. Endocrinol. Invest. 34, 60–64 (2011).
Giustina, A. et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010). This consensus statement re-evaluates and updates the guidelines on criteria for cure of acromegaly.
Giustina, A. et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85, 526–529 (2000).
Polanco-Briceno, S., Glass, D. & Plunkett, C. Communication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer Adherence 10, 2531–2541 (2016).
Cannavo, S., Trimarchi, F. & Ferrau, F. Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden. Mol. Cell Endocrinol. 457, 81–88 (2017).
Raappana, A., Koivukangas, J., Ebeling, T. & Pirila, T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J. Clin. Endocrinol. Metab. 95, 4268–4275 (2010).
Bex, M. et al. AcroBel—the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007).
Zarool-Hassan, R., Conaglen, H. M., Conaglen, J. V. & Elston, M. S. Symptoms and signs of acromegaly: an ongoing need to raise awareness among healthcare practitioners. J. Prim. Health Care 8, 157–163 (2016).
Galerneau, L. M. et al. Acromegaly in sleep apnoea patients: a large observational study of 755 patients. Eur. Respir. J. 48, 1489–1492 (2016).
Sesmilo, G. et al. Prevalence of acromegaly in patients with symptoms of sleep apnea. PLOS ONE 12, e0183539 (2017).
Heinrich, D. A. et al. IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. Endocrine 60, 317–322 (2018).
Rosario, P. W. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14, 217–221 (2011).
Rosario, P. W. & Calsolari, M. R. Screening for acromegaly in adult patients not reporting enlargement of the extremities, but with arterial hypertension associated with another comorbidity of the disease. Arq. Bras. Endocrinol. Metabol. 58, 807–811 (2014).
Cuevas-Ramos, D. et al. A structural and functional acromegaly classification. J. Clin. Endocrinol. Metab. 100, 122–131 (2015). This paper classifies patients with acromegaly by clinical, radiological and histopathological characteristics and identifies three types of acromegaly that have distinctive tumour structure–function characteristics and treatment responsiveness.
Melmed, S., Braunstein, G. D., Horvath, E., Ezrin, C. & Kovacs, K. Pathophysiology of acromegaly. Endocr. Rev. 4, 271–290 (1983).
Vortmeyer, A. O. et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune–Albright syndrome. J. Clin. Endocrinol. Metab. 97, 2404–2413 (2012).
Zhou, C. et al. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J. Clin. Invest. 125, 1692–1702 (2015).
Occhi, G. et al. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J. Neuroendocrinol. 23, 641–649 (2011).
Regazzo, D. et al. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp - somatotropinomas. Eur. J. Endocrinol. 176, 543–553 (2017).
Melmed, S. Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7, 257–266 (2011). This review describes the pathogenesis of dysregulated pituitary cell proliferation that underlies pituitary tumorigenesis.
Pei, L. & Melmed, S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11, 433–441 (1997).
Fuertes, M. et al. Protein stabilization by RSUME accounts for PTTG pituitary tumor abundance and oncogenicity. Endocr. Relat. Cancer 25, 665–676 (2018).
Xiao, J. Q. et al. Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis. PLOS ONE 9, e90396 (2014).
Chesnokova, V. et al. p21(Cip1) restrains pituitary tumor growth. Proc. Natl Acad. Sci. USA 105, 17498–17503 (2008).
Ye, Z. et al. Common variants at 10p12.31, 10q21.1 and 13q12.13 are associated with sporadic pituitary adenoma. Nat. Genet. 47, 793–797 (2015).
Valimaki, N. et al. Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 100, 3918–3927 (2015).
Lecoq, A. L., Kamenicky, P., Guiochon-Mantel, A. & Chanson, P. Genetic mutations in sporadic pituitary adenomas—what to screen for? Nat. Rev. Endocrinol. 11, 43–54 (2015).
Hage, M. et al. Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 103, 1929–1939 (2018).
Bi, W. L. et al. Clinical identification of oncogenic drivers and copy-number alterations in pituitary tumors. Endocrinology 158, 2284–2291 (2017).
Melmed, S. Medical progress: acromegaly. N. Engl. J. Med. 355, 2558–2573 (2006).
Garby, L. et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J. Clin. Endocrinol. Metab. 97, 2093–2104 (2012).
Melmed, S., Ezrin, C., Kovacs, K., Goodman, R. S. & Frohman, L. A. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N. Engl. J. Med. 312, 9–17 (1985).
Rostomyan, L. & Beckers, A. Screening for genetic causes of growth hormone hypersecretion. Growth Horm. IGF Res. 30–31, 52–57 (2016). This paper presents an in-depth description of genetic abnormalities in various genes, including AIP, MEN1, CDKN1B and PRKAR1A , which are potentially involved in GH hypersecretion by pituitary tumours.
Cazabat, L. et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J. Clin. Endocrinol. Metab. 97, E663–E670 (2012).
Caimari, F. & Korbonits, M. Novel genetic causes of pituitary adenomas. Clin. Cancer Res. 22, 5030–5042 (2016). This article presents an overview of germline and somatic mutations that lead to pituitary adenomas.
Schofl, C. et al. Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. J. Clin. Endocrinol. Metab. 99, E2789–E2793 (2014).
Reid, T. J. et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin. Endocrinol. 72, 203–208 (2010).
Kreitschmann-Andermahr, I. et al. Diagnosis and management of acromegaly: the patient’s perspective. Pituitary 19, 268–276 (2016).
Grynberg, M., Salenave, S., Young, J. & Chanson, P. Female gonadal function before and after treatment of acromegaly. J. Clin. Endocrinol. Metab. 95, 4518–4525 (2010).
Chanson, P., Salenave, S. & Kamenicky, P. Acromegaly. Handb. Clin. Neurol. 124, 197–219 (2014).
Kropf, L. L., Madeira, M., Vieira Neto, L., Gadelha, M. R. & de Farias, M. L. Functional evaluation of the joints in acromegalic patients and associated factors. Clin. Rheumatol. 32, 991–998 (2013).
Scarpa, R. et al. Acromegalic axial arthropathy: a clinical case-control study. J. Clin. Endocrinol. Metab. 89, 598–603 (2004).
Mazziotti, G. et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008).
Wassenaar, M. J. et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur. J. Endocrinol. 164, 475–483 (2011).
Tagliafico, A. et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. J. Clin. Endocrinol. Metab. 93, 905–909 (2008).
Bihan, H. et al. Long-term outcome of patients with acromegaly and congestive heart failure. J. Clin. Endocrinol. Metab. 89, 5308–5313 (2004).
Alexopoulou, O. et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17, 81–89 (2014).
Freda, P. U. et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J. Clin. Endocrinol. Metab. 93, 2334–2343 (2008).
Katznelson, L. Alterations in body composition in acromegaly. Pituitary 12, 136–142 (2009).
Attal, P. & Chanson, P. Endocrine aspects of obstructive sleep apnea. J. Clin. Endocrinol. Metab. 95, 483–495 (2010).
Herrmann, B. L. et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur. J. Endocrinol. 151, 309–315 (2004).
Delhougne, B. et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J. Clin. Endocrinol. Metab. 80, 3223–3226 (1995).
Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555–559 (2011). This consensus statement discusses how to improve the measurement of GH and IGF1 levels.
Bidlingmaier, M. et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J. Clin. Endocrinol. Metab. 99, 1712–1721 (2014).
Chanson, P. et al. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J. Clin. Endocrinol. Metab. 101, 3450–3458 (2016). This study attempts to establish normative data for six IGF1 assay kits on the basis of a large, random sample of the French adult population.
Freda, P. U., Reyes, C. M., Nuruzzaman, A. T., Sundeen, R. E. & Bruce, J. N. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6, 175–180 (2003).
Dimaraki, E. V., Jaffe, C. A., DeMott-Friberg, R., Chandler, W. F. & Barkan, A. L. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J. Clin. Endocrinol. Metab. 87, 3537–3542 (2002).
Arafat, A. M. et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J. Clin. Endocrinol. Metab. 93, 1254–1262 (2008).
Ribeiro-Oliveira, A. Jr., Faje, A. T. & Barkan, A. L. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur. J. Endocrinol. 164, 17–22 (2011).
Carmichael, J. D., Bonert, V. S., Mirocha, J. M. & Melmed, S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 523–527 (2009).
Beckers, A. et al. X-Linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr. Relat. Cancer 22, 353–367 (2015).
Karimova, M. M. et al. Pachydermoperiostosis masquerading as acromegaly. J. Endocr. Soc. 1, 109–112 (2017).
Sun, Y. et al. Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat. Genet. 44, 1375–1381 (2012).
Joustra, S. D. et al. IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management. J. Clin. Endocrinol. Metab. 101, 1627–1636 (2016).
Potorac, I. et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr. Relat. Cancer 22, 169–177 (2015).
Knosp, E., Steiner, E., Kitz, K. & Matula, C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33, 610–617; discussion 617–618 (1993).
Micko, A. S., Wohrer, A., Wolfsberger, S. & Knosp, E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J. Neurosurg. 122, 803–811 (2015).
Attal, P. & Chanson, P. Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile? Endocrine 61, 4–6 (2018).
Schneider, H. J. et al. A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J. Clin. Endocrinol. Metab. 96, 2074–2080 (2011).
Kong, X., Gong, S., Su, L., Howard, N. & Kong, Y. Automatic detection of acromegaly from facial photographs using machine learning methods. EBioMedicine 27, 94–102 (2018).
Kimmell, K. T., Weil, R. J. & Marko, N. F. Multi-modal management of acromegaly: a value perspective. Pituitary 18, 658–665 (2015).
Colao, A. et al. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). Eur. J. Endocrinol. 171, 263–273 (2014).
Melmed, S. et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009).
Melmed, S. Pituitary medicine from discovery to patient-focused outcomes. J. Clin. Endocrinol. Metab. 101, 769–777 (2016).
Lloyd, R. V., Osamura, R. Y., Kloppel, G. & Rosai, J. (eds) WHO Classification of Tumours of Endocrine Organs. 4th edn (IARC, Paris, 2017).
Raverot, G. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–G24 (2018).
Casanueva, F. F. et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary 20, 489–498 (2017).
Mercado, M. et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J. Clin. Endocrinol. Metab. 99, 4438–4446 (2014).
Colao, A., Auriemma, R. S. & Pivonello, R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19, 210–221 (2016).
van der Lely, A. J. et al. Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20, 692–701 (2017).
Giustina, A. et al. SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary 19, 39–49 (2016).
Melmed, S. et al. A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14, 552–561 (2018). This consensus statement is an update on the medical management of acromegaly.
Colao, A. et al. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J. Endocrinol. Invest. 29, 1017–1020 (2006).
Colao, A. et al. Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82, 518–523 (1997).
Sandret, L., Maison, P. & Chanson, P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011).
Giustina, A. et al. Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J. Endocrinol. Invest. 37, 1017–1030 (2014).
Gadelha, M. R. et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875–884 (2014).
Colao, A. et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014).
Duarte, F. H., Jallad, R. S. & Bronstein, M. D. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine 54, 306–314 (2016).
Stone, J. C., Clark, J., Cuneo, R., Russell, A. W. & Doi, S. A. Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies. Pituitary 17, 284–295 (2014).
Fleseriu, M., Hoffman, A. R. & Katznelson, L., AACE Neuroendocrine and Pituitary Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State clinical review: management of acromegaly patients: what is the role of pre-operative medical therapy? Endocr. Pract. 21, 668–673 (2015).
Grasso, L. F., Pivonello, R. & Colao, A. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr. Opin. Endocrinol. Diabetes Obes. 19, 288–294 (2012).
Zhang, L. et al. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis. Brain Dev. 37, 181–190 (2015).
Pita-Gutierrez, F. et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLOS ONE 8, e61523 (2013).
Tutuncu, Y. et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 15, 398–404 (2012).
Auriemma, R. S. et al. Octreotide-LAR versus lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J. Endocrinol. Invest. 31, 956–965 (2008).
Carmichael, J. D., Bonert, V. S., Nuno, M., Ly, D. & Melmed, S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 1825–1833 (2014).
Caron, P. J. et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99, 1282–1290 (2014).
Gadelha, M. R., Wildemberg, L. E., Bronstein, M. D., Gatto, F. & Ferone, D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20, 100–108 (2017).
Brzana, J., Yedinak, C. G., Gultekin, S. H., Delashaw, J. B. & Fleseriu, M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16, 490–498 (2013).
Puig-Domingo, M. et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 95, 4973–4978 (2010).
Potorac, I. et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr. Relat. Cancer 23, 871–881 (2016).
Shen, M. et al. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 58, 1057–1065 (2016).
Colao, A. et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur. J. Endocrinol. 157, 579–587 (2007).
Giustina, A. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161, 331–338 (2009).
Giustina, A. et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 102, 2454–2464 (2017).
Fleseriu, M., Rusch, E. & Geer, E. B., ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55, 247–255 (2017).
Ciresi, A., Radellini, S., Guarnotta, V. & Giordano, C. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. BMC Endocr. Disord. 18, 2 (2018).
Lovato, C. M. & Kapsner, P. L. Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. BMJ Case Rep. https://doi.org/10.1136/bcr-2017-219686 (2018).
Shimon, I. et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62, 448–455 (2018).
Schmid, H. A. et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53, 210–219 (2016).
Samson, S. L. Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR. Drugs 76, 1235–1243 (2016).
Grasso, L. F., Auriemma, R. S., Pivonello, R. & Colao, A. Adverse events associated with somatostatin analogs in acromegaly. Expert Opin. Drug Saf. 14, 1213–1226 (2015).
Giustina, A. et al. Pegvisomant in acromegaly: an update. J. Endocrinol. Invest. 40, 577–589 (2017).
van der Lely, A. J. et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589–1597 (2012).
Freda, P. U. et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr. Pract. 21, 264–274 (2015).
Trainer, P. J. et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000).
Neggers, S. J. et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 99, 3644–3652 (2014).
Sievers, C. et al. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary 18, 916–923 (2015).
Abu Dabrh, A. M. et al. Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis. Endocr. Pract. 21, 943–956 (2015).
Hannon, M. J., Barkan, A. L. & Drake, W. M. The role of radiotherapy in acromegaly. Neuroendocrinology 103, 42–49 (2016).
Biermasz, N. R., Pereira, A. M., Smit, J. W., Romijn, J. A. & Roelfsema, F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J. Clin. Endocrinol. Metab. 90, 2731–2739 (2005).
Badia, X., Webb, S. M., Prieto, L. & Lara, N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual. Life Outcomes 2, 13 (2004).
Webb, S. M., Badia, X. & Surinach, N. L., Spanish AcroQol Study Group. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur. J. Endocrinol. 155, 269–277 (2006).
Schipper, H., Clinch, J. J. & Olweny, C. L. M. in Quality of Life Assessments in Clinical Trials (ed. Spilker, B.) (Raven Press, New York, 1990).
Andela, C. D., Scharloo, M., Pereira, A. M., Kaptein, A. A. & Biermasz, N. R. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18, 752–776 (2015).
Andela, C. D. et al. The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary 19, 293–302 (2016).
Geraedts, V. J. et al. Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front. Endocrinol. (Lausanne) 8, 40 (2017).
Tiemensma, J. et al. Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J. Clin. Endocrinol. Metab. 95, E392–E402 (2010).
Pantanetti, P., Sonino, N., Arnaldi, G. & Boscaro, M. Self image and quality of life in acromegaly. Pituitary 5, 17–19 (2002).
Webb, S. M. Quality of life in acromegaly. Neuroendocrinology 83, 224–229 (2006).
Roerink, S. H. et al. Persistent self-consciousness about facial appearance, measured with the Derriford appearance scale 59, in patients after long-term biochemical remission of acromegaly. Pituitary 18, 366–375 (2015).
Rubeck, K. Z. et al. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur. J. Endocrinol. 163, 717–726 (2010).
Postma, M. R. et al. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur. J. Endocrinol. 166, 585–592 (2012).
Kyriakakis, N., Lynch, J., Gilbey, S. G., Webb, S. M. & Murray, R. D. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin. Endocrinol. 86, 806–815 (2017). This study evaluates factors that influence QOL in patients with acromegaly with long-term biochemical remission.
Liu, S. et al. Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J. Investig. Med. 66, 653–660 (2018).
Trainer, P. J. et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. Eur. J. Endocrinol. 179, 97–108 (2018).
Melmed, S. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013).
Gadelha, M. R., Kasuki, L. & Korbonits, M. The genetic background of acromegaly. Pituitary 20, 10–21 (2017).
Nature Reviews Disease Primers thanks M. Buchfelder, S. Webb and J. Jorgensen, and other anonymous reviewer(s), for their contribution to the peer review of this work.
P.C. has received unrestricted research and educational grants from Ipsen, Novartis and Pfizer as Head of the Department of Endocrinology and Reproductive Diseases, Hôpitaux Universitaires Paris-Sud. P.C. has served as an investigator (principal or coordinator) for clinical trials funded by Antisense, Chiasma, Ipsen,, Italfarmaco, Novartis and Pfizer. P.C. is a member of advisory boards from Ipsen and Novartis. P.C. gave lectures for Ipsen, Novartis and Pfizer. All the fees and honoraria were paid to his institution. S.M. receives investigator-initiated research grants from Ono and Pfizer to his institution. S.M. serves as a consultant for Chiasma, Ionis and Ipsen. A.C. has been a principal investigator of research studies from Ipsen, Lilly, Novartis and Pfizer; has received research grants from Ferring, Ipsen, Lilly, Merck-Serono, Novartis, Novo-Nordisk and Pfizer; has been an occasional consultant for Ipsen, Novartis and Pfizer; and has received fees and honoraria from Ipsen, Novartis and Pfizer. R.P. has been principal investigator of research studies for HRA Pharma and Novartis; has received research grants from Novartis, IBSA, Ipsen, Pfizer and ViroPharma; has been an occasional consultant for Ferring, Ipsen, Italfarmaco, Novartis, Pfizer, and ViroPharma; and received lecture fees and honoraria from Novartis, Pfizer and Shire. A.G. is a consultant for Ipsen, Novartis and Pfizer. L.F.S.G. and A.M.P. declare no competing interests.
The authors affirm that human research participants provided informed consent for publication of the images in Figure 2.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Colao, A., Grasso, L.F.S., Giustina, A. et al. Acromegaly. Nat Rev Dis Primers 5, 20 (2019). https://doi.org/10.1038/s41572-019-0071-6
This article is cited by
Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases
Scientific Reports (2022)
Densely granulated adenoma pattern is associated with an increased risk of obstructive sleep apnea in patients with acromegaly
Sleep and Breathing (2022)
Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review
Diabetology International (2022)
Journal of Endocrinological Investigation (2022)